Literature DB >> 21373917

[Nonalcoholic steatohepatitis. Predictor and consequence of diabetes].

N Stefan1, H-U Häring.   

Abstract

Nonalcoholic fatty liver (NAFL) and particularly nonalcoholic steatohepatitis (NASH) are not only risk factors for liver fibrosis, liver cirrhosis and hepatocellular carcinoma, but are also strongly associated with insulin resistance and type 2 diabetes. This is probably due to the fact that the same mechanisms are operative in the pathogenesis of these diseases. In addition fatty liver predicts incident type 2 diabetes, but also atherosclerosis, indicating a causal role of fatty liver in the pathogenesis of these diseases. This hypothesis is supported by novel findings deriving from translational research involving precise genotyping and phenotyping strategies in humans. The precise investigation of mechanisms involved will deliver new knowledge which may be important for the prevention and therapy of these diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21373917     DOI: 10.1007/s00108-010-2712-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  Association of fetuin-A level and diabetes risk.

Authors:  Norbert Stefan; Hans-Ulrich Häring; Matthias B Schulze
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

2.  The impact of liver fat vs visceral fat in determining categories of prediabetes.

Authors:  K Kantartzis; J Machann; F Schick; A Fritsche; H-U Häring; N Stefan
Journal:  Diabetologia       Date:  2010-01-23       Impact factor: 10.122

Review 3.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.

Authors:  Michael Roden
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-06

4.  Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations.

Authors:  S F Solga; A Alkhuraishe; K Cope; A Tabesh; J M Clark; M Torbenson; P Schwartz; T Magnuson; A M Diehl; T H Risby
Journal:  Biomarkers       Date:  2006 Mar-Apr       Impact factor: 2.658

5.  Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.

Authors:  Andreas Peter; Konstantinos Kantartzis; Jürgen Machann; Fritz Schick; Harald Staiger; Fausto Machicao; Erwin Schleicher; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2010-09-14       Impact factor: 9.461

6.  Identification and characterization of metabolically benign obesity in humans.

Authors:  Norbert Stefan; Konstantinos Kantartzis; Jürgen Machann; Fritz Schick; Claus Thamer; Kilian Rittig; Bernd Balletshofer; Fausto Machicao; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Arch Intern Med       Date:  2008-08-11

7.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

8.  Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study.

Authors:  Eva Fisher; Norbert Stefan; Kathrin Saar; Dagmar Drogan; Matthias B Schulze; Andreas Fritsche; Hans-Georg Joost; Hans-Ulrich Häring; Norbert Hubner; Heiner Boeing; Cornelia Weikert
Journal:  Circ Cardiovasc Genet       Date:  2009-09-05

9.  Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.

Authors:  Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

10.  Plasma fetuin-A levels and the risk of type 2 diabetes.

Authors:  Norbert Stefan; Andreas Fritsche; Cornelia Weikert; Heiner Boeing; Hans-Georg Joost; Hans-Ulrich Häring; Matthias B Schulze
Journal:  Diabetes       Date:  2008-07-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.